← Back to Search

Other

Subarachnoid Hemorrhage for Subarachnoid Hemorrhage

N/A
Waitlist Available
Led By Edward T Van Matre, PharmD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0-20 days
Awards & highlights
No Placebo-Only Group

Summary

This study evaluates the pharmacokinetic profile of levetiracetam in critically ill patients who have suffered a subarachnoid hemorrhage. The patients will be evaluated for development of augmented renal clearance and the effects and duration of effects this may have on levetiracetam clearance.

Eligible Conditions
  • Subarachnoid Hemorrhage

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-20 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0-20 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in systemic levetiracetam clearance over time
Secondary study objectives
Change in urinary clearance of levetiracetam and creatinine

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Subarachnoid HemorrhageExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,804 Previous Clinical Trials
2,822,128 Total Patients Enrolled
1 Trials studying Subarachnoid Hemorrhage
30 Patients Enrolled for Subarachnoid Hemorrhage
Edward T Van Matre, PharmDPrincipal InvestigatorUniversity of Colorado School of Pharmacy
~2 spots leftby Nov 2025